Tagged with HCV

Egypt Under the auspices of a wide-ranging Vision 2030 economic transformation plan, Egypt is moving towards covering the entirety of its 100 million plus population under a universal healthcare insurance scheme. Via direct presidential initiatives, the country has also made significant progress in tackling diseases like hepatitis C and breast cancer,…

Cell & Gene Therapy The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s quest for knowledge, costing USD three billion across 13 years. But even after nearly two decades, we have barely scratched…

China Rogers Luo Yongqing, global VP and general manager (China), Gilead Sciences, shares the key accomplishments of Gilead in China with six innovative products approved in just 15 months; the strategic significance of Gilead China as the newest affiliate for Gilead globally; and their commitment to maximizing patient access in China…

Canada Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of managing the financial costs of breakthrough therapies, and Gilead’s success in advancing innovative therapies in the fields of HIV and…

Pharma André Lüscher of Gilead Switzerland, reveals how the case of Sovaldi demonstrates the challenges for a healthcare system to handle a truly disruptive medical innovation, the knock-on effect on Gilead´s business model, and ensuring that those affected with hepatitis C are able to receive treatment in Switzerland. A lot has…

Pharma Former Egyptian Minister of Health Adel Adawy discusses the reforms needed in the Egyptian healthcare system and the progress made in the fight against HCV over the last two years. What structural changes need to be made in the Egyptian healthcare system? First of all, Egypt needs to have three…

Pharma OrganoPharma’s founder and chairman Dr. Mowfak Sakr explains how he founded his company to try and provide the 40 million people in Egypt who lack healthcare insurance of any kind with safe, effective, and affordable medicines, and shares his vision for expanding the company internationally. Dr. Sakr, what is OrganoPharma…